Ionis Q1 Revenue Soars 87% to $246M While Loss Narrows to $75M
Ionis reported Q1 revenue up 87% to $246M and non-GAAP operating loss narrowed to $75M; cash totaled $1.9B at quarter-end. The company raised olezarsen peak net sales guidance to over $3B and set June 30 and September 22 PDUFA targets for sHTG and Alexander disease.
1. Q1 Financial Results
For the quarter ended March 31, 2026, Ionis recorded total revenue of $246 million, an 87% increase year-over-year. GAAP operating loss improved to $118 million versus $146 million, while non-GAAP operating loss narrowed to $75 million from $117 million, reflecting higher commercial and R&D revenues.
2. Cash Position and Capital Deployment
Cash and short-term investments stood at $1.9 billion at quarter-end, after the company used $633 million to redeem convertible notes maturing April 1, 2026. Operating expenses rose in line with expectations due to continued investments in commercial launches and R&D programs.
3. Product Launches and Sales
Net product sales for independent launches included $27 million for TRYNGOLZA and $16 million for DAWNZERA, the latter rising 125% versus the prior quarter. Ionis also recognized $95 million in R&D revenue from clinical and regulatory milestones across multiple partnerships and initiated EU launches for both therapies.
4. Guidance and Pipeline Milestones
Ionis increased its annual olezarsen peak net sales guidance to over $3 billion from $2 billion, reflecting confidence in the severe hypertriglyceridemia market. The company has PDUFA target dates of June 30 for sHTG and September 22 for Alexander disease filings, with Phase 3 cardiovascular outcome trials due later this year.